Pascal Guibord

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

David Isenberg, Richard Furie, Nicholas S. Jones et al. · Arthritis & Rheumatology · 2021 · 126 citations

Determination of Naproxen Using DBS: Evaluation & Pharmacokinetic Comparison of Human Plasma Versus Human Blood DBS

Nikolay Youhnovski, Josée Michon, Sylvain Latour et al. · Bioanalysis · 2010 · 21 citations

OP0233 EFFICACY, SAFETY, AND PHARMACODYNAMIC EFFECTS OF THE BRUTON'S TYROSINE KINASE INHIBITOR, FENEBRUTINIB (GDC-0853), IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS IN A PHASE 2 CONTROLLED STUDY

David Isenberg, Richard Furie, Nicholas S. Jones et al. · Annals of the Rheumatic Diseases · 2020 · 18 citations · Full text